Carbamazepine-associated drug reaction with eosinophilia and systemic symptoms syndrome
Author(s) -
Ankush Sharma,
Ekta Joshi,
Nitin Gupta,
Monika Joshi
Publication year - 2021
Publication title -
journal of pediatric neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
eISSN - 1998-3948
pISSN - 1817-1745
DOI - 10.4103/jpn.jpn_126_15
Subject(s) - medicine , carbamazepine , sulfasalazine , eosinophilia , hypersensitivity reaction , dapsone , mucocutaneous zone , methylprednisolone , phenytoin , drug , adverse drug reaction , dermatology , pharmacology , anesthesia , immunology , epilepsy , disease , psychiatry , ulcerative colitis
Drug reaction with eosinophilia and systemic symptoms syndrome is a severe type IV (delayed T-cell-dependent reaction) hypersensitivity reaction, characterized by fever, mucocutaneous eruptions, eosinophilia, and systemic inflammatory involvement. It usually begins a few weeks after the exposure to offending drug. Commonly implicated drugs are aromatic anticonvulsants (phenytoin, phenobarbitone, and carbamazepine) and sulfa drugs (sulfonamides, sulfasalazine, and dapsone). It is a potentially life-threatening hypersensitivity reaction. Here we report a case of drug reaction with eosinophilia and systemic symptoms syndrome associated with carbamazepine, which was successfully treated with intravenous methylprednisolone.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom